Literature DB >> 25599130

Indirect measures of arterial stiffness and cognitive performance in individuals without traditional vascular risk factors or disease.

Jose Gutierrez1, Randolph S Marshall1, Ronald M Lazar1.   

Abstract

IMPORTANCE: Whether cognition is influenced by arterial stiffness in the absence of vascular disease remains uncertain.
OBJECTIVE: To test the hypotheses that indirect measures of arterial stiffness are important predictors of cognitive performance and that this relationship varies depending on the presence of vascular disease. DESIGN, SETTING, AND PARTICIPANTS: Participants included 2573 noninstitutionalized US adults randomly selected from 2 cycles of the National Health and Nutrition Examination Survey (1999-2002). The sample was stratified by groups based on the presence (VASC+) vs the absence (VASC-) of vascular variables negatively associated with cognition to assess the effects of indirect measures of arterial stiffness on cognitive performance. We used logistic regression to obtain odds ratios (ORs) and their 95% CIs. P < .05 was considered statistically significant. MAIN OUTCOMES AND MEASURES: The Digit Symbol Substitution Test score was used as a continuous variable, and the lowest quintile was designated as an indicator of poorer cognitive performance.
RESULTS: In the VASC+ group, poorer cognitive performance was more likely with increasing age (OR, 1.12 [95% CI, 1.08-1.17]; P < .001), a sedentary lifestyle (OR, 2.99 [95% CI, 1.62-5.55]; P = .002), and the use of dihydropyridine calcium channel blockers (OR, 9.24 [95% CI, 1.35-63.23]; P = .02). Poorer cognitive performance in the VASC+ group was less likely in women (OR, 0.37 [95% CI, 0.18-0.72]; P = .02), non-Hispanic white individuals (OR, 0.16 [95% CI, 0.09-0.26]; P < .001), those with higher educational attainment (OR, 0.23 [95% CI, 0.14-0.38]; P < .001), those with higher income levels (OR, 0.56 [95% CI, 0.72-0.76]; P < .001), and those who used renin-angiotensin system blockers (OR, 0.24 [95% CI, 0.07-0.79]; P = .02). In the VASC- group, the most important significant predictors of poorer cognitive performance were an ankle brachial index greater than 1.30 (OR, 18.56 [95% CI, 2.94-117.05]; P = .002) and increased blood pressure variability (OR, 3.49 [95% CI, 1.07-11.35]; P = .04). Among participants in the VASC- group who had both of these variables, the prevalence of poorer cognitive performance was greater (β = 16.65; P < .001). CONCLUSIONS AND RELEVANCE: Two indirect measures of arterial stiffness, an ankle brachial index greater than 1.30 and increased blood pressure variability, are associated with poorer cognitive performance among adults 60 years or older without clinical atherosclerotic disease. Among those with vascular disease, factors capable of influencing arterial stiffness, such as exercise and the use of renin-angiotensin system blockers, may be protective against poorer cognitive performance.

Entities:  

Mesh:

Year:  2015        PMID: 25599130      PMCID: PMC8985655          DOI: 10.1001/jamaneurol.2014.3873

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  36 in total

Review 1.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-11-11       Impact factor: 29.690

2.  What do adult age differences in the Digit Symbol Substitution Test reflect?

Authors:  T A Salthouse
Journal:  J Gerontol       Date:  1992-05

3.  Racial and ethnic disparities in stroke subtypes: a multiethnic sample of patients with stroke.

Authors:  Jose Gutierrez; Sebastian Koch; Chuanhui Dong; Teresita Casanova; Royya Modir; Michael Katsnelson; Gustavo A Ortiz; Ralph L Sacco; Jose G Romano; Tatjana Rundek
Journal:  Neurol Sci       Date:  2013-10-15       Impact factor: 3.307

4.  Ankle-brachial index as an indicator of arterial stiffness in patients without peripheral artery disease.

Authors:  Simon W Rabkin; Siu Him Chan; Colleen Sweeney
Journal:  Angiology       Date:  2011-06-15       Impact factor: 3.619

5.  A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes.

Authors:  F G Quigley; I B Faris; H J Duncan
Journal:  Clin Physiol       Date:  1991-01

Review 6.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

7.  Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.

Authors:  Lawrence S Honig; Walter Kukull; Richard Mayeux
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

8.  Presence of carotid and peripheral arterial disease in patients with left main disease.

Authors:  Aaron L Doonan; Juhana Karha; Thomas P Carrigan; Anthony A Bavry; Susan M Begelman; Stephen G Ellis; Jay Yadav; Deepak L Bhatt
Journal:  Am J Cardiol       Date:  2007-07-18       Impact factor: 2.778

9.  Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.

Authors:  Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson
Journal:  Neurology       Date:  2013-08-02       Impact factor: 9.910

10.  Aortic stiffness, blood pressure progression, and incident hypertension.

Authors:  Bernhard M Kaess; Jian Rong; Martin G Larson; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Gary F Mitchell
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

View more
  6 in total

Review 1.  Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline.

Authors:  Maggie Wang; Jennifer E Norman; Vivek J Srinivasan; John C Rutledge
Journal:  Am J Neurodegener Dis       Date:  2016-11-30

2.  Sex and Age Differences in the Association of Blood Pressure and Hypertension with Cognitive Function in the Elderly: The Rancho Bernardo Study.

Authors:  D Kritz-Silverstein; G A Laughlin; L K McEvoy; E Barrett-Connor
Journal:  J Prev Alzheimers Dis       Date:  2017

3.  Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Rianne A A de Heus; Christophe Tzourio; Emily Jo Lynn Lee; Melissa Opozda; Andrew D Vincent; Kaarin J Anstey; Albert Hofman; Kazuomi Kario; Simona Lattanzi; Lenore J Launer; Yuan Ma; Rajiv Mahajan; Simon P Mooijaart; Michiaki Nagai; Ruth Peters; Deborah Turnbull; Yuichiro Yano; Jurgen A H R Claassen; Phillip J Tully
Journal:  Hypertension       Date:  2021-09-20       Impact factor: 9.897

Review 4.  Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami Effect in the Brain?

Authors:  Naoki Saji; Kenji Toba; Takashi Sakurai
Journal:  Pulse (Basel)       Date:  2016-01-20

5.  The association between pulse pressure change and cognition in late life: Age and where you start matters.

Authors:  Eric McDade; Zhaowen Sun; Ching-Wen Lee; Beth Snitz; Tiffany Hughes; Chung-Chou H Chang; Mary Ganguli
Journal:  Alzheimers Dement (Amst)       Date:  2016-06-11

6.  Biomarkers of Exposure to Polycyclic Aromatic Hydrocarbons and Cognitive Function among Elderly in the United States (National Health and Nutrition Examination Survey: 2001-2002).

Authors:  Elizabeth A Best; Elizabeth Juarez-Colunga; Katherine James; William G LeBlanc; Berrin Serdar
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.